PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab'. Together they form a unique fingerprint.

Medicine & Life Sciences